<DOC>
	<DOCNO>NCT00384423</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics PRX-03140 administer orally daily 14 day subject mild Alzheimer 's Disease use stable , well-tolerated 10 mg dose Aricept ( donepezil ) continue experience worsening AD symptom .</brief_summary>
	<brief_title>Short Term Effects PRX-03140 Patients With Mild Alzheimer 's Disease Being Treated With Aricept</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>At least 60 year old . On stable 10 mg dose Aricept least 90 day able take morning . Diagnosis probable Alzheimer 's Disease . Mild dementia . You authorize representative provide voluntary write informed consent . Not pregnant , planning pregnancy , capable become pregnant . Any medical condition , opinion Investigator , would jeopardize safety , impact validity study result , interfere ability complete study accord protocol . Intolerance Aricept . Dementia Alzheimer 's type . Parkinson 's Disease . History seizure epilepsy . History stroke . Participation another research study within last 30 day . Enrollment previous research study test PRX03140 . Use prescription cognitive enhance medication ( except Aricept ) MAO inhibitor within last 4 week . Use tobacco product within last 4 week . Positive blood screen Hepatitis B surface antigen Hepatitis C antibody . Positive urine screen alcohol drug abuse history drug alcohol abuse within last 6 month . Major surgery within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>AD</keyword>
	<keyword>PRX-03140</keyword>
	<keyword>Dementia</keyword>
	<keyword>Epix</keyword>
	<keyword>Predix</keyword>
	<keyword>Cognition enhance</keyword>
</DOC>